Frontier Medicines’ Post

Check out CEO Murat Cirit's conversation with Brad Loncar from BiotechTV about humanizing drug discovery with the #LiverTissueChip and Javelin platform. Javelin human tissue chips bring both human complexity and specificity for acute and chronic studies. The chips generate longitudinal, high-content, and human-relevant data. Javelin AI-enabled digital twin technology analyzes multi-modal chip data and translates to human responses to design better medicines faster. #AlignSummit24

Excellent interview from Mathai Mammen, M.D., Ph.D. ..."80% of proteins are undruggable…. Why are most things undruggable"? "...there was a time in the late 90s, drugs were found thru phenotypic screening… most targets were Zion channels…as we saw inflection after inflection of data, sequencing data, we find more and more targets coming forward that are intracellular protein interactions, far more complicated to inhibit with small molecules… to do so it needs a covalent handle OR it needs a cavity, hydropic or creatable from a non-existent pocket (cryptic)…it is possible to find something cryptic. What FogPharma has done is to create a kind of motif that we interfere with protein-to-protein interactions. Does nature put large structures inside cells? Yes, viruses do it all day long… they use alpha helices… this is very important… next level of problem is can we use that, but most protein structures want to be something else… fog learned how to stabilize a structure in a alpha helices. These are not easy to construct. Fog has now 100s of ways to stich an alpha helix. This is an entire revolution and now it doesn’t matter what the composition is and allows astronomical diversity in terms of amino acid placement..” #biotech #fog #proteinengineering #innovation #lifesciences

Sharing some insight into what we're doing at #fogpharma, and why we're excited:   Our modality is nature-inspired, but uses synthetic chemistry to access chemical diversity well beyond what can be found in nature. We then combine it with powerful screening and data science platforms to enable #Helicon design, removing barriers to some of the most important disease targets in cancer and beyond

Nurix’s CEO, Arthur T. Sands, M.D., Ph.D., discussed Nurix’s differentiated BTK degraders NX-5948 and NX-2127 and promising new safety and efficacy data that were presented at #ASH2023 with Brad Loncar on BiotechTV. Watch the interview below.

In case you missed it: Last week, Ali, our CEO, caught up with Brad Loncar from BiotechTV to discuss all things ETX! During their conversation Ali delved into our innovative computational approach to development of GalOmic #RNAi therapies and discussed our experience of the dynamics of London’s capital markets. Watch the interview below! #AI #Biotech

In today's fast-paced and innovation-driven economy, intellectual property (IP) assets have emerged as a cornerstone for businesses, especially those in technology, pharmaceuticals, and creative industries....

BLUE DOT LIST: Relative Strength Line can be your Game-Changing Tool – Hbl Power Systems, Zydus Lifesciences, Pb Fintech, Elgi Equipments hitting new high in RS Line Read here in detail - https://lnkd.in/guUB2fWQ Disclaimer - https://lnkd.in/dnR9KgSV

It is late November. You know what that means... ✅ It is time to prepare for #JPM2024! Before finalizing your schedule, check out the annual JPM Guide from BioCentury Inc. and MacDougall Advisors. ✅ Access the JPM Guide: www.jpmguide.com Three tips: ➤ Bookmark the JPM Guide. It is the definitive list of sideline events and receptions during JPM week in January in SF. ➤ Memorize the JPM Guide: Make sure you know the closest event at all times, aka, don't get caught out in the rain (or hail)! ➤ Take advantage of the JPM Guide: Don't miss the special offers, including a collection of BioCentury essays on dealmaking and finance. ✅ Bonus tip: If you want to standout in SF, start working on truly unique complaints about #JPM24. Cross out: Location, prices, weather, off-base pitches from BD teams or communications firms, and so forth. Let's all resolve to test at least one new complaint at JPM 2024! Happy holidays to all. I look forward to seeing you in San Francisco! #biotech #pharma #biopharma #venturecapital

When you squeeze a balloon, the air goes somewhere. Same with the cost of drugs. PRECISIONvalue expert Andrew Cournoyer, SVP of the Access Experience Team, explains the anticipated fallout from the Inflation Reduction Act in this 90-second video. Watch now. #pharmamarketing #marketaccess #drugpricing #inflationreductionact #ira"

𝗢𝘇𝗲𝗺𝗽𝗶𝗰, 𝗠𝗼𝘂𝗻𝗷𝗮𝗿𝘆, 𝗪𝗲𝗴𝗼𝘃𝘆, 𝗢𝘇𝗲𝗺𝗽𝗶𝗰, 𝗠𝗼𝘂𝗻𝗷𝗮𝗿𝘆, 𝗪𝗲𝗴𝗼𝘃𝘆, 𝗢𝘇𝗲𝗺𝗽𝗶𝗰, 𝗠𝗼𝘂𝗻𝗷𝗮𝗿𝘆, 𝗪𝗲𝗴𝗼𝘃𝘆, 𝗢𝘇𝗲𝗺𝗽𝗶𝗰, 𝗠𝗼𝘂𝗻𝗷𝗮𝗿𝘆, 𝗪𝗲𝗴𝗼𝘃𝘆, 𝗢𝘇𝗲𝗺𝗽𝗶𝗰, 𝗠𝗼𝘂𝗻𝗷𝗮𝗿𝘆, 𝗪𝗲𝗴𝗼𝘃𝘆 Fueled by a newfound obsession with these drugs, investors and ETF issuers are seeking new ways to gain exposure to the healthcare sector, leading to the emergence of a new niche theme. Here's our lead analyst Tony Dong, MSc, CETF®'s latest take on the topic 👇